Home
/ SML
/ Competitors

SML Competitors and Similar CompaniesClear all

SML's competitors and similar companies include Endologix, Apria Healthcare Group, Acelity and Shanghai Sanyou Medical.

	SML SML is a company that designs and constructs orthodontic and orthopedic appliances.	Endologix Endologix is a medical device company that provides therapies for the treatment of vascular disease.	Apria Healthcare Group Apria Healthcare Group is a company that provides home respiratory services and medical equipment.	Acelity Acelity is a medical device company offering wound therapeutics products.	Shanghai Sanyou Medical Shanghai Sanyou Medical (上海三友医疗器械股份有限公司) researches, develops, manufactures, and supplies orthopedics implant products.
Founding Date	Founding Date 1957	Founding Date 1992	Founding Date N/A	Founding Date 1976	Founding Date 2005
Type	Type Private	Type Subsidiary	Type Subsidiary	Type Subsidiary	Type Public
Tags	Tags Healthcare medical devices therapy	Tags Healthcare medical devices therapy	Tags Healthcare medical devices therapy	Tags Healthcare medical devices therapy	Tags Healthcare medical devices therapy
Locations	Locations Los Angeles, US HQ	Locations Irvine, US HQ 's Hertogenbosch, NL Milpitas, US Santa Rosa, US	Locations Indianapolis, US HQ Lake Forest, US	Locations San Antonio, US HQ Lane Cove West, AU Wien, AT Wien, AT Mississauga, CA see more	Locations CN HQ
Employees	Employees 40	Employees 4351% increase	Employees 5,666	Employees 2,106	Employees 466
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $143.4m (FY, 2019)	Revenue (est.) $1.1b (FY, 2021)	Revenue (est.) N/A	Revenue (est.) ¥446m (FY, 2024)
Cost of goods	Cost of goods N/A	Cost of goods $52.3m (FY, 2019)	Cost of goods $341.3m (FY, 2021)	Cost of goods N/A	Cost of goods ¥130m (FY, 2024)
Gross profit	Gross profit N/A	Gross profit $91.1m (FY, 2019)	Gross profit $804m (FY, 2021)	Gross profit N/A	Gross profit ¥317.9m (FY, 2024)
Net income	Net income N/A	Net income ($64.8m) (FY, 2019)	Net income $64.9m (FY, 2021)	Net income N/A	Net income ¥12.1m (FY, 2024)